Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.71 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7155458 | 0.88 | AURKA (0.73) | AURKAHPSEPRMT5METAP2METAP1 | |
| SCHEMBL7155380 | 0.88 | AURKA (0.64) | AURKAHPSEPRMT5 | |
| SCHEMBL14091556 | 0.81 | ACHE (0.70) | AURKAHPSEPRMT5 | |
| SCHEMBL7155725 | 0.81 | AURKA (0.47) | AURKAMETAP2METAP1 | |
| SCHEMBL7549644 | 0.80 | ACHE (0.64) | HPSE | |
| SCHEMBL7550838 | 0.80 | ACHE (0.45) | AURKAHPSE | |
| SCHEMBL7158378 | 0.79 | PDE5A (0.55) | AURKAMETAP2METAP1 | |
| SCHEMBL7160843 | 0.77 | AURKA (0.51) | AURKAHPSEPRMT5 | |
| SCHEMBL11770396 | 0.76 | AURKA (0.70) | AURKAHPSEPRMT5METAP2METAP1 | |
| SCHEMBL7159653 | 0.76 | AURKA (0.66) | AURKAHPSEPRMT5METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | AURKA 4675/4885HPSE 3358/4885PRMT5 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.